Ciglitazone inhibits GBM growth mainly through the activation of SHP-2 to impede the formation of phospho-STAT3, as well as activate the proteosome and lysosome to degrade cell-cycle-associated proteins. The gene discussed is STAT3; the disease is glioblastoma.